Gunnar Staaf

Gunnar Staaf has extensive experience in the field of corporate development. Gunnar began their career in 1994 as a Business Unit Manager for Eli Lilly and Company. Gunnar then moved to Novartis in 2005 as a Business Franchise Head. In 2006, they became the European Brand Director for Astellas Pharma. In 2008, they were hired as the Commercial Director for Serentis Ltd. In 2009, they became the Chief Executive Officer for Avantium Pharmaceuticals, where they successfully completed a Management Buy-Out (MBO) in 2011. Following the MBO, they became the Owner & Chief Executive Officer of Crystallics. In 2020, they were hired as a Director for Valand Property Group. In 2021, they became the Chief Business Officer for Exvastat. Finally, in 2019, they became a Partner for CCD Partners.

Gunnar Staaf has an education history that includes an MBA from the University of Warwick - Warwick Business School, which they obtained between 1994 and 1995. Gunnar also has a BA (hons) in Economics and Accounting from the University of Reading, which they obtained between 1986 and 1989.